Safety and tolerability of sequential pegylated IFN-α2a and tenofovir for hepatitis B infection in HIV+ individuals

Raymond M. Johnson, M. B. Ristig, E. T. Overton, M. Lisker-Melman, O. W. Cummings, J. A. Aberg

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Chronic hepatitis B virus infections are a major cause of morbidity and mortality in HIV co-infected patients. The standard of care for treating HCV co-infection has been guided by major clinical trials, but the treatment of HBV co-infection has not been as thoroughly studied and the standard of care remains largely untested. The single pill formulation of tenofovir with emtricitabine has become a standard treatment approach in HBV co-infected patients. WU114 was a phase 1 clinical trial that examined the safety and tolerability of sequential treatment of HBV with pegylated interferon-α2a plus delayed-initiation tenofovir in HIV co-infected individuals. We postulated that initial HBV viral load reduction with pegylated interferon prior to initiation of nucleoside/nucleotide therapy would increase seroconversion events and durability of HBV virologic suppression. No severe pegylated IFN-α2a drug toxicities were seen in either the monotherapy or delayed tenofovir arms. Sequential pegylated interferon and tenofovir-based therapy was tolerable and should be compared with dual nucleoside/nucleotide suppression to determine relative frequencies of seroconversion and durability of HBV suppression in co-infected patients.

Original languageEnglish (US)
Pages (from-to)173-181
Number of pages9
JournalHIV Clinical Trials
Volume8
Issue number3
DOIs
StatePublished - May 2007

Keywords

  • HBV
  • HIV
  • Phase 1 clinical trial
  • Resistance
  • Suppression

ASJC Scopus subject areas

  • Virology
  • Immunology

Fingerprint Dive into the research topics of 'Safety and tolerability of sequential pegylated IFN-α2a and tenofovir for hepatitis B infection in HIV+ individuals'. Together they form a unique fingerprint.

  • Cite this